• Immutep jumps 13% after getting fast-track status for its drug to treat head and neck cancer

    3 days ago - By Business Insider

    Summary List Placement Immutep jumped as much as 13% to two-week highs on Thursday after the biotechnology company announced that its lead drug candidate for recurrent or metastatic head and neck cancer has received a fast track status from the US Food and Drug Administration.
    Immutep was up 8% to $3.45 as of 12:00 p.m. ET, having risen to a session peak of $3.59 earlier in the day, its highest since March 25.
    Immutep is listed on the Australian Securities Exchange and on the Nasdaq.
    The drug candidate, eftilagimod alpha or efti, is a soluble LAG-3 protein aimed to become the first line...
    Read more ...

     

  • Immutep jumps 13% after getting fast-track status for its drug to treat head and neck cancer

    Immutep jumps 13% after getting fast-track status for its drug to treat head and neck cancer

    3 days ago - By Business Insider

    A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland.
    Sarah Silbiger/Getty Images
    Immutep jumped as much as 13% on Thursday to a two-week high.
    The company's lead drug candidate for head and neck cancer received fast track status from the FDA.
    Immutep is listed on the Australian Securities Exchange and on the Nasdaq.
    Sign up here for our daily newsletter, 10 Things Before the Opening Bell
    Immutep jumped as much as 13% to two-week highs on Thursday after the biotechnology company announced that its lead drug candidate for...
    Read more ...